New hope for elderly myeloma patients: drug combo trial launches

This phase 3 trial is testing whether adding the drug isatuximab to a standard combination of lenalidomide and dexamethasone, with or without bortezomib, can improve outcomes for newly diagnosed multiple myeloma patients aged 65 to 79 who are not eligible for a stem cell transplant. The study will enroll 270 participants and measure how well the treatment reduces cancer cells to very low levels. The goal is to find a more effective and tolerable treatment option for this older population.